Drug Trial Radar · NCT03778450
Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany
Last checked: Nov 19, 2026Latest source record: Sep 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,232
Actual
Start
Dec 5, 2018
Primary completion
Aug 31, 2019
Study completion Aug 31, 2019
Sponsor
- Lead sponsor
- LinkCare GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH; Klinikum Saarbrücken; Ruhr University of Bochum; Technical University of Munich
- First posted
- Dec 19, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Among patients receiving opioids for noncancer pain, recent research in North America showed a strong association between doses and opioid-related mortality, especially at dosages exceeding thresholds recommended in recent guidelines. However, the focus on over-dosage may underestimate overall opioid-related mortality and data on death associated with opioid use in a population-based cohort of chronic noncancer pain patients in Europe is scarce. Especially comparative studies studying the safety of long-term opioid therapy in a real-world setting relative to non-opioid medication for chronic noncancer pain are needed in a European context.
Conditions
- Pain
Interventions
Analgesics, OpioidDrug
Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients.
Non-Opioid AnalgesicDrug
Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 2013 - 2017
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LinkCare GmbH
Stuttgart, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.